Dimethyl Fumarate: all 58 studies that test it

Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)Not yet recruitingNCT07483632Phase 3
• Randomised Evaluation of COVID-19 TherapyRecruitingNCT04381936Phase 3
• Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic AtrophyRecruitingNCT04292080Phase 2
• Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric ParticipantsTerminatedNCT03870763Phase 3Results posted
• Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial HypertensionTerminatedNCT02981082Phase 1Results posted
• Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLLTerminatedNCT02784834Phase 1Results posted
• Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)CompletedNCT02739542Phase 4Results posted
• Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)CompletedNCT02555215Phase 3Results posted
• Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).CompletedNCT02525874Phase 3Results posted
• Dimethyl Fumarate for Obstructive Sleep ApneaCompletedNCT02438137Phase 2Results posted
• BG00012 and Delay of Disability Progression in Secondary Progressive Multiple SclerosisTerminatedNCT02430532Phase 3Results posted
• Tecfidera Slow-Titration StudyTerminatedNCT02428231Phase 3Results posted
• Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMSCompletedNCT02410200Phase 2Results posted
• Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)CompletedNCT02283853Phase 3Results posted
• Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In GermanyCompletedNCT02125604Phase 4Results posted
• Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.CompletedNCT02097849Phase 2Results posted
• Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United StatesCompletedNCT01873417Phase 4Results posted
• Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl FumarateCompletedNCT01568112Phase 3Results posted
• BG00012 Phase 2 Combination Study in Participants With Multiple SclerosisCompletedNCT01156311Phase 2Results posted
• BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)CompletedNCT00835770Phase 3Results posted
• Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple SclerosisCompletedNCT00451451Phase 3Results posted
• Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple SclerosisCompletedNCT00420212Phase 3Results posted
• Dimethyl Fumarate in AdrenomyeloneuropathyActive, not recruitingNCT06513533Phase 2/3
• Dimethyl Fumarate Treatment for Intracranial Unruptured Aneurysms.CompletedNCT05959759Phase 4
• A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in ChinaCompletedNCT05658484Phase 4
• Combination of the Immune Modulator Dimethyl Fumarate With Intraarterial Treatment in Acute Ischemic StrokeWithdrawnNCT04891497Phase 2
• Dimethyl Fumarate for the Treatment of Intracerebral HemorrhageWithdrawnNCT04890379Phase 2
• Combination of the Immune Modulator Dimethyl Fumarate With Alteplase in Acute Ischemic StrokeStatus unknownNCT04890366Phase 1/2
• Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic StrokeTerminatedNCT04890353Phase 1/2
• Fingolimod Versus Dimethyl-fumarate in Multiple SclerosisTerminatedNCT03345940Phase 4
• Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive PatientsStatus unknownNCT03092544Phase 4
• Dimethyl Fumarate Treatment of Primary Progressive Multiple SclerosisCompletedNCT02959658Phase 2
• Study of the Effects of the Organism on Monomethyl Fumarate (MMF) After the Administration of LAS41008CompletedNCT02955693Phase 1
• Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarateTerminatedNCT02901106Phase 4
• Pharmacokinetics of DMF and the Effects of DMF on Exploratory BiomarkersCompletedNCT02683863Phase 4
• Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MSWithdrawnNCT02675413Phase 4
• Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012CompletedNCT02579681Phase 3
• Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)CompletedNCT02546440Phase 2
• Proof-of-concept Study of Forward Pharma (FP)187 in Patients With Mild/Moderate Psoriatic ArthritisWithdrawnNCT02475304Phase 2
• Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple SclerosisWithdrawnNCT02472938Phase 4
• Tecfidera and the Gut MicrobiotaCompletedNCT02471560Phase 4
• Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple SclerosisCompletedNCT02461069Phase 4
• Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)WithdrawnNCT02428218Phase 3
• Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT02337426Phase 1
• A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial ManufacturersCompletedNCT02171208Phase 1
• Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl FumarateWithdrawnNCT02090348Phase 4
• A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported OutcomesCompletedNCT01930708Phase 4
• BG00012 Regional Absorption StudyCompletedNCT01924832Phase 1
• An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)CompletedNCT01838668Phase 3
• Efficacy Study on Dimethyl Fumarate to Treat Moderate to Severe Plaque PsoriasisWithdrawnNCT01815723Phase 3
• LAS41008 in Moderate to Severe Chronic Plaque PsoriasisCompletedNCT01726933Phase 3
• Phase 1 Study to Evaluate the PK, Safety, and Tolerability of BG00012 in Chinese, Japanese, and Caucasian Healthy VolunteersCompletedNCT01453426Phase 1
• Alternate Dosing Regimens of BG00012 in Healthy VolunteersCompletedNCT01281111Phase 1
• Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque PsoriasisCompletedNCT01230138Phase 2
• Pharmacokinetics Profile Study of BG00012 Standard Formulation and BG00012 Active Pharmaceutical IngredientCompletedNCT01069913Phase 1
• A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MSCompletedNCT00837785Phase 1
• Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active Rheumatoid ArthritisCompletedNCT00810836Phase 2
• Efficacy and Safety of BG00012 in MSCompletedNCT00168701Phase 2

← Dimethyl Fumarate overview